Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 2/3 × NSCLC × Gefitinib × Clear all

Phase

Phase 2/3 2 Phase NA 1 Phase 3 1 Phase 2 1 Phase 1 1

Status

Unknown 1 Completed 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 NSCLC 2 Brain Neoplasms 2 Respiratory Tract Diseases 1 Neoplasms 1 Lung Neoplasms 1

Interventions

Pemetrexed 2 Gefitinib 2 spartalizumab 1 aflutinib 1 Tyrosine Kinase Inhibitors 1 Thalidomide 1 Radiosurgery 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00259064 2016-06-02

INSTEP

AstraZeneca

Phase 2/3 Completed

NSCLC

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡